Vertex to buy Semma Therapeutics for $950m in cash
Vertex to acquire ViaCyte, targeting type 1 diabetes
Vertex's Stem Cell-Based Type 1 Diabetes Therapy To Enter Human Trial Stage | The Healthcare Technology Report.
Vertex reports positive results for first patient in Type 1 diabetes trial - The Boston Globe
JDRF Canada - Breaking News: Vertex Pharmaceuticals announced they acquired ViaCyte for $320 million in cash to help speed up the development of VX-880, Vertex's stem cell-derived therapy for people with type
Vertex builds up pipeline of type 1 diabetes cell therapies with $320M buyout - MedCity News
Why stem cells may be the answer to curing Type 1 diabetes
Vertex Forward: Diving into type 1 diabetes | Vertex
JDRF Report: Vertex Has a New Horizon: Curing Type 1 Diabetes
Vertex Moves Full Steam Ahead on Type 1 Diabetes Drug Trial With FDA's OK | BioSpace
Vertex buys developer of preclinical cell therapy for Type 1 diabetes for $950M - MedCity News
Vertex – type 1 diabetes vs stem cell therapy - The Boar
FDA suspends early study of Vertex stem-cell therapy for type 1 diabetes
Vertex Pharmaceuticals am 52-Wochenhoch – Studie für Stammzellentherapie gegen Diabetes-Typ-1 wird fortgesetzt!
ViaCyte's Future 'Functional Diabetes Cure' for Diabetes
AKTIONÄR-Tipp Vertex: Übernahme – Aktie auf Jahreshoch - DER AKTIONÄR
Vertex Releases New Data on Potential Cure for Type 1 Diabetes
Frontiers | Stem Cell-Based Clinical Trials for Diabetes Mellitus
ViaCyte Acquisition Can Accelerate Vertex's Ongoing Type 1 Diabetes Programs
Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes - PMLiVE
Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff | The Motley Fool
Felicia Pagliuca en LinkedIn: Type 1 diabetes is a significant burden on individuals, on families, on…
A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked. - The New York Times
FDA fast tracks type 1 diabetes cell therapy from Vertex | Pharmaphorum
